Bayer Sidesteps Dilution with Debt-Funded Settlement as Finerenon Trial Bolsters Pipeline
12.06.2026 - 08:14:17 | boerse-global.de
Bayer has quashed lingering fears of a rights issue by confirming it will finance its $7.25 billion Roundup class-action settlement entirely through existing credit lines. The company tapped $8 billion in bank loans to cover the agreement, eliminating any equity dilution for current shareholders – a move analysts have praised as a display of financial discipline. The decision comes as the group simultaneously rolls out promising clinical data from its pharma pipeline, offering a dual narrative of legal risk containment and drug development momentum.
The restructuring burden, however, is considerable. Dr. Judith Hartmann, who took over as chief financial officer on 1 June, inherits a balance sheet under pressure: Bayer expects negative free cash flow of roughly €5 billion this year, predominantly from litigation payouts. Management has ruled out a capital increase and plans to bridge the gap with loans and bonds. The consumer health division, while growing top-line sales to €1.49 billion in the first quarter, saw adjusted EBITDA slip 1.5% to €337 million, squeezed by higher marketing costs and adverse currency moves.
On the pharma front, Bayer notched a significant win with Finerenon, marketed as Kerendia. The phase III FIND-CKD study in non-diabetic chronic kidney disease met its endpoints, showing the drug slows kidney function decline and cuts the risk of major cardiovascular events. Results were presented in early June in Glasgow and simultaneously published in the New England Journal of Medicine. The company now plans to submit the data to the US Food and Drug Administration to expand Kerendia’s label beyond its current approval for certain patients with type 2 diabetes and heart failure. Separately, the FDA granted a fast-track designation in May for Finerenon in type 1 diabetes – a potential first-in-class indication.
Should investors sell immediately? Or is it worth buying Bayer?
The stock price reflects the tug-of-war between legal overhang and pipeline promise. Shares closed at €35.93 on Thursday, hovering just below the 200-day moving average of €35.95. A sustained break above that level would be seen as a bullish signal, and the relative strength index suggests the stock is not yet overbought. Analysts at UBS reiterated their buy rating with a €52 target, citing the management’s two-pronged strategy of resolving litigation while delivering solid results in pharma and crop science.
A series of near-term events will decide the next leg. In July, US courts are expected to give final approval to the $7.25 billion settlement. Around the same time, the Supreme Court will rule in the Durnell case, a decision with implications for many outstanding glyphosate claims. Meanwhile, the European Medicines Agency is reviewing Asundexian, another key pipeline asset. If the legal picture clears and the pharma catalysts materialise, the stock could finally break free from the technical resistance that has pinned it near flat territory for the year.
Ad
Bayer Stock: New Analysis - 12 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
